Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 19 of 65 · 3101 articles
Crohn’s disease prevalence and new diagnoses are rising rapidly in Korea, especially among people in their 20s and 30s; that affects demand for diagnosis, long-term care, and affordable treatment.
This meta-analysis pulls together early trial evidence that TL1A antagonists may improve clinical, endoscopic, and histologic outcomes in both UC and CD and reports an overall acceptable short-term safety...
The study suggests a mechanism (reduced intestinal oxalate transport) that could make common “healthy” plant foods aggravate intestinal inflammation in some people with Crohn’s or ulcerative colitis, which could affect...
This work looks for molecular signals that might help explain how long-term ulcerative colitis can be connected to higher colorectal cancer risk. Identifying shared genes and spatial patterns could eventually guide...
New oral micro- and nanomedicine strategies aim to deliver drugs more selectively to diseased areas in the gut, which could eventually improve treatments for IBD and colorectal cancer by increasing local effects and...
Researchers planned to study whether patterns in the gut microbiome correlate with clinical diagnoses (including Crohn’s and UC), which could inform future biomarker work. The study is suspended, so no results are...
Understanding how patient-derived epithelial cells respond to inflammation could reveal mechanisms of poor mucosal healing in IBD and identify targets or biomarkers to improve repair. Organoid models from patient tissue...
A randomized trial tested whether adding dapagliflozin (an SGLT2 inhibitor) to mesalamine changes disease activity in adults with mild–moderate ulcerative colitis over 6 months. If effective and safe, it could suggest a...
This Phase 2 trial is testing a new oral drug (ATH-063) for adults with moderately to severely active ulcerative colitis who have not responded to prior biologic or advanced therapies, a group that often needs additional...
A validated, disease-specific self-care scale could help measure and track self-management behaviors that affect daily life and clinical outcomes for people with IBD, and support research and clinical care focused on...
Patients and clinicians using ustekinumab may be able to use an early (around 3 months) drug concentration to help predict short-term remission, while routine repeated monitoring later on may be less informative for...
The paper proposes molecular links between Crohn’s disease and Alzheimer’s disease through two genes implicated in inflammation and tissue remodeling. This could shape future research into shared gut–brain inflammatory...
This highlights a new, biologically distinct drug target (IL‑7Rα) in ulcerative colitis that may help patients who do not respond to existing biologics, and it summarizes early clinical evidence for lusvertikimab while...
The study uses a mouse model of ulcerative colitis to test hemp seed oil and reports molecular and metabolic changes alongside reduced disease in the model. Patients and researchers may be interested because it explores...
A colon-targeted form of febuxostat reduced inflammation in a rat colitis model while keeping blood levels low, suggesting a way to repurpose an existing drug for IBD with potentially fewer systemic effects.
A plant-derived polysaccharide improved inflammation, gut barrier markers, and metabolic measures in a mouse model of diabetes-linked ulcerative colitis — findings that could point to new research directions for...
Patient-informed refinements to ePRO design and study operations could reduce burden and missing data in high-frequency daily symptom reporting, which matters for study quality and for patients asked to report symptoms...
Perceived stress affects quality of life and may influence symptom burden, disease management, and mental health in people with IBD. Updated PSQ benchmarks from a contemporary cohort help researchers and clinicians...
The study suggests that asymptomatic C. difficile colonization may not predict return of IBD activity in patients who are in remission, which could influence how clinicians interpret positive C. difficile tests in people...
Cure8 found this source from bioengineer.org, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.
Antibiotics can cause microbiome injury that increases risk of C. difficile and may worsen long-term health issues; identifying ways to protect the gut microbiome during antibiotic use could be especially relevant for...
The project investigates how TNFR1 and TNFR2 differently control epithelial repair in the colon—mechanisms that may explain why many patients on anti‑TNF biologics do not achieve lasting mucosal healing and could point...
Many people with IBD have ongoing IBS-like symptoms despite little or no intestinal inflammation. This project targets brain–gut and autonomic mechanisms that might explain symptom persistence and tests a non-drug...
The project targets a molecular regulator of tuft cells, which help control mucosal immune responses and have been linked to chronic gut inflammation such as ulcerative colitis. Discovering how OCA-T2 shapes tuft cell...
This project describes a novel off-the-shelf engineered regulatory T cell therapy aiming to promote intestinal immune regulation and mucosal healing — a different approach than current biologics. If successful, it could...
The study tests whether common environmental chemicals (PFAS) could alter protein glycosylation and raise the later risk of IBD, which could point to preventable risk factors and early biomarkers.
The paper identifies epothilone B as a repurposing candidate that may reduce neutrophil-driven inflammation and support epithelial healing in IBD models, a potential new strategy distinct from broad neutrophil...
The study identifies epithelial IFN‑I signaling as a driver of barrier failure in anti‑TNF refractory Crohn’s disease and suggests that blocking IFN‑I could be a rescue strategy for patients who do not respond to...
miRNAs are being studied as stable circulating biomarkers and possible therapeutic targets in immune diseases including IBD. Advances could eventually improve earlier diagnosis, track disease course, or lead to new...
The study links a traditional acupuncture-derived technique (ACE) to reduced colitis severity in rats and to modulation of the cGAS–STING immune pathway and macrophage marker profiles, suggesting a potential mechanistic...
The pipeline helps identify stem and progenitor epithelial cell states linked to inflammation in IBD. Knowing these cell states and biomarkers could guide research into disease mechanisms, tissue repair, and potential...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Research and clinical trials. The original article is from Crohn's & colitis 360.
Cocaine use can trigger severe GI problems that mimic common surgical and inflammatory conditions; recognizing the link can speed diagnosis and management. Most published evidence is low-level (case reports/series), so...
Mucosal colonisation by adherent‑invasive E. coli has been implicated in Crohn’s disease for some patients; this study suggests FMT can change the mucosal microbiome and clear AIEC in a small pilot cohort, which could be...
This large national-registry study identifies clinical features linked with needing optimization of biologic or small-molecule therapies in CD and UC. That helps show which patient groups more often require...
Undernutrition and lean-mass loss are common and harmful in people with IBD. If dietary strategies can prevent weight and muscle loss and shift the gut microbiota toward SCFA producers, that could be relevant to...
Findings about increased LRRK2 in colonic tissue may point to shared immune or genetic mechanisms between Crohn’s disease and neurological disorders, which could be relevant for future research and biomarker development.
SMC phenotypic switching can contribute to intestinal fibrosis and motility problems in IBD; understanding macrophage regulation of SMCs could point to new treatment targets for these complications.
The review suggests LJF contains compounds that may reduce intestinal inflammation, support gut barrier health, and influence microbiota—areas directly relevant to ulcerative colitis and colorectal cancer risk. However,...
Mechanical forces in the gut may help drive fibroblast activation and early fibrosis in IBD; models that reproduce this could help researchers study and eventually target fibrotic pathways relevant to stricturing...
The study suggests starting anti-TNF therapy with an immunomodulator at diagnosis may reduce surgery, hospital stays, and progression to complicated Crohn’s over 5 years — outcomes that matter to patients and clinicians...
Histology and endoscopy are both used to assess UC activity; knowing which histologic score is reliable and practical helps clinicians and pathologists standardize monitoring and may streamline reporting in routine care.
A noninvasive, explainable model that combines CT enterography radiomics with CRP could make it easier to monitor mucosal healing in small‑bowel Crohn’s disease without repeated invasive enteroscopy, especially after...
The study suggests a new macrophage-linked mechanism (NINJ2 → ZBP1 → PANoptosis) that may drive intestinal inflammation in IBD and could become a target for future therapies or biomarkers.
Shifting care toward disease modification could reduce long-term bowel damage and disability for people with Crohn's disease by prioritizing earlier, more effective treatment and exploring prevention strategies.
The study suggests ED presentation symptoms predict admission differently in UC versus CD, which could affect triage and short-term risk assessment for IBD patients. Knowing which symptoms are stronger predictors by...
NOD2 loss-of-function is a major genetic risk for Crohn’s disease, and this review highlights that gut microbes can modulate NOD2 signaling. That connection may help explain variation in disease risk and points to...
Early effective treatment may change long-term outcomes in Crohn's disease. Understanding the timing of a potential "window of opportunity" could affect decisions about when to start or escalate therapy.
